TITLE:
Guanfacine for the Treatment of Post Traumatic Stress Disorder (PTSD)

CONDITION:
Post-Traumatic Stress Disorder

INTERVENTION:
guanfacine

SUMMARY:

      This is a double-blind, placebo-controlled, randomized study lasting 8 weeks. Purpose of the
      study is two-fold: first, to use a pharmacological agent to treat symptoms of PTSD, and
      second, to explore neurobiological mechanisms of action of guanfacine.
    

DETAILED DESCRIPTION:

      Subject population is comprised of 100 persons with PTSD. 50 patients will receive
      guanfacine and 50 patients will receive a placebo. Guanfacine is prescribed at 1 mg/day and
      may be increased to 2 mg/day. Samples of plasma MHPG will be collected weekly. Clinical
      ratings of PTSD anxiety and depression, as well as vital signs, will be assessed weekly.
      Repeated measures analysis of variance will assess significance of main effect of drug,
      time, and drug by time.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to 65 Years
Criteria:

        -  Males and females, age 18-65

          -  Diagnosis of PTSD from combat or civilian trauma

          -  No major medical problems such as diabetes, cardiovascular disease

          -  Taking no psychiatric medication, or taking only one SSRI antidepressant
      
